Search / Trial NCT00001085

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of December 10, 2023

Completed

Keywords

Hiv 1 Drug Therapy, Combination Acquired Immunodeficiency Syndrome Zidovudine Hiv Protease Inhibitors Lamivudine Rna, Viral Vx 478 Reverse Transcriptase Inhibitors Anti Hiv Agents Viral Load

Description

Although dramatic inhibition of HIV-1 replication is achieved with ritonavir or indinavir monotherapy, in both cases maximum suppression required combination treatment together with nucleoside analog RT inhibitors. This study tests the hypothesis that monotherapy with 141W94 doses that result in Cmin levels far in excess of the IC90 corrected for plasma protein binding for HIV-1 can achieve the same virologic and immunologic effects in terms of magnitude and durability, as has been observed with combinations of other protease inhibitors plus nucleoside analogs. In this randomized, double-b...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Chemoprophylaxis for Pneumocystis carinii pneumonia is required for all patients who have a CD4 cell count <= 200 cells/mm3.
  • Topical and/or oral antifungal agents, except for those listed in excluded medications.
  • Treatment, maintenance or chemoprophylaxis with approved agents for opportunistic infections as clinically indicated, unless listed in excluded medications.
  • All antibiotics as clinically indicated.
  • Systemic corticosteroid use for <= 21 days for acute problems is permitted as medically indicated; chronic systemic corticosteroid use is not permitted.
  • Recombinant erythropoietin and granulocyte colony-stimulating factor as medically indicated.
  • Regularly prescribed medications such as:
  • antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives (a barrier method is also required for this study), megestrol acetate, testosterone or any other medications, as medically indicated.
  • Alternative therapies such as vitamins, acupuncture and visualization techniques are permitted (excluding herbal medications).
  • NOTE:
  • Patients should report the use of these therapies; alternative therapies will be recorded.
  • Patients must have:
  • HIV-1 infection as documented by ELISA and confirmed.
  • >= 5,000 HIV-1 RNA copies/ml (within 30 days prior to study entry).
  • CD4 cell count >= 50 cells/mm3 within 60 days prior to study entry.
  • Signed, informed consent for patients < 18 years of age.
  • Prior Medication: Required:
  • Patients must be on a stable antiretroviral regimen for 30 days prior to study screening and remain on the same regimen until entry.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Any active infection requiring acute treatment within 14 days prior to entry.
  • A malignancy that requires systemic therapy other than minimal Kaposi's sarcoma.
  • NOTE:
  • Patients with minimal Kaposi's sarcoma, defined as <= 5 cutaneous lesions and no visceral disease or tumor-associated edema, will be allowed to enroll as long as they do not require systemic therapy for Kaposi's sarcoma.
  • Patients with the following prior symptoms and conditions are excluded:
  • Inability to tolerate ZDV 500-600 mg daily if ZDV was administered previously. Intolerance to ZDV is defined as any grade toxicity that resulted in a dose reduction or termination of ZDV.
  • Prior Medication:
  • Excluded:
  • Any 3TC therapy prior to entry.
  • Any HIV-1 protease inhibitor therapy prior to study entry (e.g., saquinavir, ritonavir, indinavir, nelfinavir, 141W94).
  • Any immunomodulator therapy within 30 days prior to entry.
  • Active immunization within 30 days prior to entry.
  • Any antiretroviral therapy change within 30 days prior to study screening.
  • 1. Concurrent use of non-protocol specified antiretroviral agents; either investigational or licensed.
  • Immunomodulators that affect immunologic or virologic indices such as systemic corticosteroids, thalidomide, or cytokines.
  • Concomitant use of rifabutin and/or rifampin.
  • Investigational drugs other than 141W94/VX-478.
  • Systemic cytotoxic chemotherapy.
  • Oral astemizole (Hismanal), carbamazepine (Tegretol), dexamethasone (Decadron), ketoconazole (Nizoral), itraconazole (Sporanox), phenobarbital, phenytoin (Dilantin), terfenadine (Seldane), cisapride (Propulsid), triazolam (Halcion) and midazolam (Versed).
  • Herbal medications.

Attachments

readout_NCT00001085_2023-12-10.pdf

4.5 MB

NCT00001085_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Birmingham, Alabama, United States

Los Angeles, California, United States

Aurora, Colorado, United States

Miami, Florida, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Saint Louis, Missouri, United States

Saint Louis, Missouri, United States

New York, New York, United States

Chapel Hill, North Carolina, United States

Philadelphia, Pennsylvania, United States

Atlanta, Georgia, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0